Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 10/2019

01-10-2019 | Ovarian Cancer | Original Article

Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma

Authors: Kazuki Takasaki, Morikazu Miyamoto, Masashi Takano, Hiroaki Soyama, Tadashi Aoyama, Hiroko Matsuura, Hideki Iwahashi, Hiroki Ishibashi, Takahiro Sakamoto, Kenichi Furuya

Published in: International Journal of Clinical Oncology | Issue 10/2019

Login to get access

Abstract

Background

This study aimed to examine the clinical significance and risk factors of thromboembolic events (TEEs) in patients with ovarian carcinoma.

Methods

Patients with ovarian carcinoma treated at our hospital between 2000 and 2017 were identified. The risk factors of TEEs, including venous TEEs and arterial TEEs, and the association between TEEs and prognosis were investigated. Patients with TEEs were classified into two groups: those with severe TEEs, defined as patients who required urgent treatment for deep vein thrombosis, massive pulmonary embolism, acute myocardial infarction, and symptomatic cerebral infarction, and those with mild TEEs. The risk factors of severe TEEs and the association between severe TEEs and prognosis were investigated.

Results

A total of 369 patients were enrolled. Among them, 53 patients (14.4%) were complicated with TEEs. Clear cell carcinoma (CCC) was a greater risk factor of TEEs than serous carcinoma (hazard ratio [HR] = 2.81, p = 0.03). In multivariate analysis for survival, TEEs were a prognostic factor of poor progression-free survival (PFS; HR = 2.90, p < 0.01) and overall survival (OS; HR = 2.89, p < 0.01). Among 53 patients with TEEs, 17 (32.1%) developed severe TEEs. CCC was strongly associated with severe TEEs (HR = 42.6, p = 0.02). Multivariate analysis for survival demonstrated that severe TEEs were a risk factor of worse PFS (HR = 4.34, p < 0.01) and OS (HR = 3.30, p = 0.03).

Conclusion

TEEs induced poor prognosis and was associated with CCC. A standard treatment for CCC should be included in the strategy of TEEs.
Literature
1.
Baldwin LA, Huang B, Miller RW et al (2012) Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 120:612–618CrossRefPubMed
2.
Burgers A, Schmalfeldt B (2011) Ovarian cancer diagnosis and treatment. Dtsch Arztebl Int 108:635–641
3.
Pujade-Lauraine E, Alexander J (2011) Update of randomized trials in recurrent disease. Ann Oncol Suppl 8:61–64
4.
5.
Naumann RW, Coleman RL (2011) Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 71:1397–1412CrossRefPubMed
6.
Li M, Li H, Liu F et al (2017) Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. J Ovarian Res 10:9CrossRefPubMedPubMedCentral
7.
8.
Miyamoto M, Takano M, Goto T et al (2013) Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review. J Gynecol Oncol 24:37–43CrossRefPubMedPubMedCentral
9.
Friedlander ML, Russel K, Millis S et al (2016) Molecular profiling of clear cell ovarian cancers: identifying potential treatment targets for clinical trials. Int J Gynecol Cancer 26:648–654CrossRefPubMedPubMedCentral
10.
11.
Sakurai M, Matsumoto M, Sakata A et al (2017) Expression of tissue factor in epithelial ovarian carcinoma is involved in the development of venous thromboembolism. Int J Gynecol Cancer 27:37–43CrossRefPubMed
12.
13.
Cohen JG, Prendergast E, Geddings JE et al (2017) Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. Gynecol Oncol 146:146–152CrossRefPubMed
14.
Ye S, Yang J, Cao D et al (2015) Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma: a 12-year retrospective study. PLoS ONE 10:1–10
15.
Kuroda H, Mabuchi S, Shigeta N et al (2014) Recurrent cerebral infarctions in patient with ovarian cancer: a fatal case of Trousseau’s syndrome. Gynecol Obstet 4:1–4CrossRef
16.
Takano H, Nakajima K, Nagayoshi Y et al (2018) Clinical associations of Trousseau's syndrome associated with cerebral infarction and ovarian cancer. J Gynecol Oncol 29:67CrossRef
17.
Tateo S, Mereu L, Salamano S et al (2005) Ovarian cancer and venous thromboembolic risk. Gynecol Oncol 99:119–125CrossRefPubMed
18.
Greco PS, Bazzi AA, Mclean K et al (2017) Incidence and timing of thromboembolic events in patients with ovarian cancer undergoing neoadjuvant chemotherapy. Obstet Gynecol 129:979–985CrossRefPubMed
19.
20.
Sorensen HT, Mellemkjaer L, Steffensen FH et al (1998) The risk of a diagnosis of cancer after deep vein thrombosis or pulmonary embolism. N Engl J Med 338:1169–1173CrossRefPubMed
21.
Naoi H, Hashimoto H, Kajimoto E et al (2013) Cerebral infarctions as manifestation of ovarian clear cell carcinoma: report of two cases and review of the literature. Int Canc Conf J 2:206–210CrossRef
22.
23.
Prat J, FIGO Committee on Gunecologic Oncology (2015) FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol 26:87–89CrossRefPubMedPubMedCentral
24.
Ebina Y, Uchiyama M, Imafuki H et al (2018) Risk factors for deep venous thrombosis in women with ovarian cancer. Medicine (Baltimore) 97:1–6CrossRef
25.
26.
Matsuo K, Hasegawa K, Yoshino K et al (2015) Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. Eur J Cancer 51:1978–1988CrossRefPubMed
27.
Koizume S, Miyagi Y (2015) Tissue factor-factor VII complex as a key regulator of ovarian cancer phenotypes. Biomarker Cancer 7:1–13
28.
Duan Z, Foster R, Bell DA et al (2006) Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 12:5055–5063CrossRefPubMed
29.
30.
31.
Yoshikawa T, Miyamoto M, Aoyama T et al (2018) JAK2/STAT3 pathway as a therapeutic target in ovarian cancers. Oncol Lett 15:5772–5780PubMedPubMedCentral
32.
Yanaihara N, Hirata Y, Yamaguchi N et al (2015) Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary. Mol Carcinog 55:832–841CrossRefPubMed
33.
Tetsche MS, Nørgaard M, Pedersen L et al (2006) Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study. BMC Cancer 6:189CrossRefPubMedPubMedCentral
34.
Einstein MH, Pritts EA, Hartenbach EM (2007) Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. Gynecol Oncol 105:813–819CrossRefPubMed
35.
Miyamoto M, Takano M, Iwaya K et al (2014) X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary. Br J Cancer 110:2881–2886CrossRefPubMedPubMedCentral
36.
Miyamoto M, Takano M, Aoyama T et al (2017) Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas. J Gynecol Oncol 28:33CrossRef
37.
Chavan DM, Huang Z, Song K et al (2017) Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer. Medicine (Baltimore) 96:e7935CrossRef
38.
Matsuura Y, Robertson G, Marsden DE et al (2007) (2007) Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 104:406–410CrossRefPubMed
39.
Kröger K, Weiland D, Ose C et al (2006) Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 17:297–303CrossRefPubMed
40.
De Martino RR, Goodney PP, Spangler EL et al (2012) Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg 55:1035–1040CrossRefPubMedPubMedCentral
Metadata
Title
Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma
Authors
Kazuki Takasaki
Morikazu Miyamoto
Masashi Takano
Hiroaki Soyama
Tadashi Aoyama
Hiroko Matsuura
Hideki Iwahashi
Hiroki Ishibashi
Takahiro Sakamoto
Kenichi Furuya
Publication date
01-10-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 10/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01464-4

Other articles of this Issue 10/2019

International Journal of Clinical Oncology 10/2019 Go to the issue

Original Article

Phase II study of S-1 on alternate days plus bevacizumab in patients aged ≥ 75 years with metastatic colorectal cancer (J-SAVER)

Original Article

Clinical significance of the pattern-based classification in endocervical adenocarcinoma, usual and variants

Letter to the Editor

Familial cancer of unknown primary

Original Article

Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer

Original Article

Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma

Original Article

A single-arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits